Trials supported by electronic health records

Trials supported by electronic health records – a game-changer for study design and execution Professor Martin Gibson will be revealing the secrets of the successful delivery of GlaxoSmithKline’s (GSK) real world Salford Lung Study at BioData World Congress 2016 on 26 October in Cambridge. Widely recognised as the first study of its kind globally, the Salford Lung Study is a …

genomeweb whitepaper

Alternative Proposals for Lab Test Regulation

Are There Opportunities for Consensus? A GenomeWeb Report February 2016 Amid multiple proposals on LDT regulation, are there opportunities for consensus? By Turna Ray The lab industry entered 2016 in a staring contest with the US Food and Drug Administration that began two years ago when the agency released its draft guidance on regulating laboratory-developed tests (LDTs). During the course …

Clinical Outsourcing

Recoding the Life Sciences Value Chain with Digital DNA

Take a look at the penetration of digital technologies within and across the life sciences value chain, and see how some organizations are digitally reimagining their businesses to drive growth, boost productivity. Life sciences companies need to generate higher revenues at reduced costs to sustain innovation. To achieve this optimal scenario, the industry is building new portfolios, expanding into new geographies, …

Essential payer insights

Using real world evidence in clinical trials is critical to the success of patient recruitment and payer engagement programs. Through more stakeholder collaboration, we can help patients access the right treatment for them. How can we achieve this in practice? How do we overcome pricing and funding challenges? How can we use data better? We put these important questions to …

Francisco Kuribreña of Landsteiner Scientific's 2015 Presentation

Landsteiner Scientific on Mexican biosimilars

We were excited to have Francisco Kuribreña, Director of New Development at Landsteiner Scientific, share his expertise on institutional experiences in preclinical evaluation of biosimilars in Mexico at last year’s World Biosimilar Congress USA. Download his presentation now > You can now download Francisco’s presentation to find out more about: The emerging Mexican economy Mexico and the pharma business The …

Hemostemix: Your cells, our technology

Valentin Fulga of Hemostemix  joined us at Stem Cells & Regenerative Medicine Congress 2014 to present ‘ Hemostemix : Your cells, our technology’  Download the presentation now to learn about Advantages of ACP-01 Ischemic heart disease clinical trial results  Diversified development & commercialization opportunities …and much more! Get your copy here!  To find out more about  diversified development and commercialization opportunities from Hemostemix , attend  Stem Cells & Regenerative …

Algorics

Press- release: Algorics releases latest version of its acuity solution

Houston, TX, USA, For Release: 5th August 2015. Algorics, a provider of clinical analytics solutions and software for the global life sciences industry, today announced the release of the latest version of its acuity solution – designed for use by pharma, biotech, CRO and academic organizations to drive regulatory compliant processes around management of risk. The acuity solution allows organizations …

“Cell Therapy Logistics: The Physics of Failure”

Dan O’Donnell of Fisher BioServices  joined us at Stem Cells & Regenerative Medicine Congress USA 2014 to present about ‘ Cell Therapy Logistics: The Physics of Failure’  Download his presentation now to understand more about: Thermal capacity Dry shipper system qualification Orientation risk The gas laws–impact …and much more! Get your copy here!  To find out more about  cell therapy logistics ,attend  Stem Cells & Regenerative Medicine …

Tata whitepaper on clinical trials

Leveraging Emerging Technologies to Improve Patient Centricity in Clinical Trials

Patient centricity is pivotal to patient recruitment and retention in clinical trials. Hence companies involved in drug development such as pharmaceutical and biotech companies try to introduce novel strategies to improve patient enrolment and satisfaction. As pharmaceutical companies compete with each other to bring more novel drugs to the market, the volunteer patient pool is fast getting depleted, due to …

Whitepaper: The assessment of cognitive safety in compounds using cloud based clinical trial information systems throughout drug development

In this whitepaper, Dr Charlotte Housden, Cambridge Cognition, acknowledges the increasing pressure on pharmaceutical companies to accelerate the development of safe and effective treatments whilst reducing the risk of failure and encouraging commercial drug differentiation. In response to this growing demand, Cambridge Cognition has developed two cloud computing products to test cognitive safety and tolerability in drug development: Clinical Trial Information System – Profile …